Vaginal Estradiol in Women 65 and Older: What You Need to Know About Safety, Efficacy, and Age-Related Considerations

Why Genitourinary Syndrome of Menopause Hits Harder After 65

Estrogen deprivation in the vaginal and urinary tissues is progressive. It does not plateau at the time of the final menstrual period. In women past age 65, the vulvovaginal epithelium has often been estrogen-depleted for 10 to 20 years, meaning tissue thinning, reduced lubrication, and urethral changes are more advanced than in women who are five years post-menopause.

The Tissue-Level Changes That Accumulate With Age

The vaginal epithelium depends on estrogen to maintain its multilayered glycogen-rich structure. Without it, the epithelium thins from roughly 30 cell layers to as few as 4 to 5, the submucosal vasculature contracts, and the vaginal pH rises above 5.0, creating conditions that favor pathogenic bacteria over protective lactobacilli. A 2016 review in Menopause confirmed that pH normalization is a reliable surrogate marker of epithelial recovery during local estrogen therapy.

Urethral tissues undergo parallel changes. The urethra shares embryologic origin with the lower vagina, and both are estrogen-sensitive. After prolonged estrogen deprivation, urethral closure pressure falls, contributing to stress and urge incontinence, and the periurethral tissues become more permeable to uropathogenic bacteria, which partly explains why recurrent urinary tract infections are more common after age 65. A Cochrane review (2023) examining estrogen for recurrent UTI prevention found low-dose vaginal estrogen reduced recurrence by approximately 36% to 75% compared with placebo or no treatment.

Prevalence and Undertreatment in the Geriatric Population

GSM affects roughly 50% of postmenopausal women, yet fewer than 25% receive treatment. The treatment gap widens with age. Women in their 70s and 80s are more likely to accept symptoms as an inevitable part of aging, and clinicians are more likely to defer prescribing because of generalized concerns about estrogen in older patients. This undertreatment has real consequences: GSM is independently associated with reduced sexual quality of life, recurrent UTIs, and increased risk of urinary incontinence-related falls in the geriatric population. A 2019 JAMA Internal Medicine study of 3,046 community-dwelling women over 65 found that urge urinary incontinence doubled the odds of a fall-related injury (OR 2.03, 95% CI 1.44 to 2.86).

How Vaginal Estradiol Works and What the Formulations Look Like

Vaginal estradiol delivers estradiol directly to the epithelial surface of the vagina and lower urinary tract. Local delivery allows therapeutic tissue concentrations at doses that keep serum estradiol well below levels associated with systemic effects. Four delivery systems are in regular clinical use for older women.

Tablets and Soft-Gel Inserts

The 10-mcg estradiol hemihydrate tablet (Vagifem, Yuvafem) is the most studied formulation in older women. It is inserted nightly for two weeks, then twice weekly. The 4-mcg and 10-mcg estradiol soft-gel inserts (Imvexxy) work similarly. At the 10-mcg dose, a pharmacokinetic sub-study of the REJOICE trial showed mean serum estradiol levels of 5.2 pg/mL, well within the postmenopausal range of <20 pg/mL. The REJOICE trial (N=764) demonstrated statistically significant reductions in the severity of the most bothersome symptom of GSM at 12 weeks for both the 4-mcg and 10-mcg inserts compared with placebo (P<0.001).

Cream

Estradiol vaginal cream (Estrace, 0.01% estradiol) delivers higher doses per application (typically 0.5 to 2 g, containing 50 to 200 mcg estradiol) than tablets or inserts, and absorption is correspondingly higher, especially in atrophic tissue where barrier function is compromised. For women over 65 starting on cream, the lowest effective dose should be identified quickly. Serum estradiol can transiently rise to systemic levels in the first few weeks of cream use in severely atrophic women before the epithelium partially reconstitutes. A pharmacokinetic study published in Menopause showed that a 0.5-g cream dose (50 mcg estradiol) in postmenopausal women with atrophy produced mean peak serum estradiol of 76 pg/mL on day 1, falling to 34 pg/mL by week 2 as mucosal barrier function improved.

The Vaginal Ring

The estradiol vaginal ring (Estring, 2 mg estradiol released at approximately 7.5 mcg per 24 hours over 90 days) provides continuous low-level local delivery. Serum estradiol remains at or below 8 pg/mL throughout the wear period. The ring is especially practical for women with manual dexterity limitations, a common issue in the 65+ population, because it requires insertion only four times per year. The FDA prescribing information for Estring confirms a mean serum estradiol of 8 pg/mL during ring use, consistent with postmenopausal baseline levels.

Systemic Absorption: Is It Clinically Meaningful in Older Women?

This is the question that most often drives prescriber hesitation. Older women have thinner, more permeable vaginal epithelium at the outset, which can mean relatively higher systemic absorption in the first weeks of therapy. The clinical significance of this transient elevation is debated.

Serum Estradiol Levels in Practice

At the 10-mcg tablet and the 7.5-mcg-per-day ring, serum estradiol stays at or below postmenopausal baseline in steady-state use. The initial weeks on vaginal cream are a different story because the epithelial barrier has not yet recovered. Clinicians treating women in their 70s and 80s who have severe atrophy should prefer a tablet or ring over cream for the first one to three months, switching to cream if desired only after some epithelial reconstitution has occurred.

Endometrial Safety

Multiple trials and systematic reviews have addressed whether low-dose vaginal estrogen thickens the endometrium enough to require progestogen co-administration. The answer, at standard low doses, is no. A 2006 trial by Vagifem investigators (N=159) followed endometrial thickness by transvaginal ultrasound over 52 weeks of 10-mcg twice-weekly use and found no significant change from baseline, with no cases of endometrial hyperplasia. The Menopause Society's 2023 position statement states directly: "Low-dose vaginal estrogen therapy does not require the addition of a progestogen in women with a uterus." The statement defines low dose as 10 mcg estradiol tablet or ring formulations at standard labeled dosing. Women on higher doses of vaginal cream should be evaluated individually.

Specific Geriatric Considerations: What Changes After 65

Prescribing vaginal estradiol to a 68-year-old who is otherwise well and taking no medications is straightforward. Prescribing to an 82-year-old with heart failure, polypharmacy, and mild cognitive impairment requires additional thought. Several age-specific factors change the benefit-risk calculation.

Polypharmacy and Drug Interactions

Vaginal estradiol at low doses has minimal hepatic first-pass metabolism and minimal CYP450 interactions at clinical serum concentrations. Women over 65 are more likely to be on anticoagulants, antiepileptics, or aromatase inhibitors. Aromatase inhibitors (anastrozole, letrozole, exemestane) used for breast cancer suppression are a direct contraindication to any form of estrogen, including vaginal formulations, unless an oncologist has specifically approved use in the context of inadequate response to non-hormonal options. The ASCO-ASTRO 2023 guidelines on endocrine therapy for breast cancer survivors specify that vaginal estrogen should not be used concurrently with aromatase inhibitors without multidisciplinary oncology review.

Cognitive Function

The relationship between estrogen and cognitive aging is complex and the timing of exposure matters. The Women's Health Initiative Memory Study (WHIMS), which studied oral conjugated equine estrogen plus medroxyprogesterone acetate in women 65 and older, found a doubled risk of dementia (HR 2.05, 95% CI 1.21 to 3.48). WHIMS results are published in JAMA. Those findings do not apply to low-dose vaginal estradiol, which produces serum levels two orders of magnitude below those achieved by oral systemic therapy. No trial to date has shown cognitive harm from local vaginal estrogen. Prescribers should document this distinction clearly in the patient chart so that future clinicians reviewing the medication list understand the rationale.

Falls and Frailty

Urinary incontinence, one of the conditions that vaginal estradiol can improve, is a modifiable fall risk. Reducing nocturia episodes in a frail 78-year-old woman reduces the number of nighttime trips to the bathroom and may directly reduce fall frequency. Clinicians should frame this benefit explicitly when discussing vaginal estradiol with older patients and their caregivers.

Cardiovascular Comorbidities

Systemic estrogen therapy is associated with increased risk of venous thromboembolism (VTE) and, at oral doses, stroke. Low-dose vaginal estradiol at tablet and ring doses does not produce serum levels high enough to activate hepatic coagulation factor synthesis in the way that oral systemic estrogen does. A nested case-control study published in BMJ (2016, N=35,000 women) found no increase in VTE risk with low-dose vaginal estrogen compared with non-users (adjusted OR 0.97, 95% CI 0.73 to 1.30). Women with active or recent VTE, active cardiovascular disease, or prior stroke should still be evaluated individually, but the systemic-estrogen thromboembolic evidence does not automatically transfer to the vaginal route at low doses.

Prescribing Guidelines and Who Should Receive This Treatment

Both major North American menopause guidelines now endorse low-dose vaginal estradiol as a first-line, age-neutral therapy for GSM.

The Menopause Society (NAMS) 2023 Position Statement

The Menopause Society's 2023 hormone therapy position statement notes that "for women whose symptoms are limited to vaginal dryness or associated discomfort with sexual activity, low-dose vaginal estrogen therapy or other vaginal therapies are preferred." The full statement is available in Menopause journal. The statement does not specify an upper age limit for treatment and explicitly includes older postmenopausal women.

The Endocrine Society Clinical Practice Guideline

The Endocrine Society's 2015 menopause guideline (reaffirmed with updates in subsequent years) recommends low-dose vaginal estrogen for GSM in postmenopausal women regardless of systemic hormone therapy status. The guideline is available through the Journal of Clinical Endocrinology and Metabolism. It notes that "the risk of endometrial stimulation is minimal" at the 10-mcg tablet dose.

Who Should Not Use Vaginal Estradiol

Absolute contraindications are limited but real. Women with unexplained vaginal bleeding require workup before initiation. Women on aromatase inhibitors for active breast cancer treatment should not use vaginal estradiol without oncology clearance. Women with estrogen-dependent uterine or ovarian cancers require individualized oncology discussion. Relative contraindications include active VTE (where even minimal systemic absorption adds theoretical risk) and severe hepatic impairment.

Starting, Monitoring, and Discontinuing Treatment in Older Patients

Initiating Therapy: Practical Steps

Before prescribing, confirm the diagnosis with a pelvic examination or, if examination is not feasible, a vaginal pH test and symptom assessment. Rule out vaginal infection, particularly bacterial vaginosis or vulvovaginal candidiasis, which can mimic GSM and will not respond to estrogen. Document the indication, formulation selected, dose, and rationale in the medical record.

For a woman starting at age 70 or older, the preferred initial formulation is the 10-mcg estradiol tablet or the estradiol vaginal ring. Begin with the labeled dosing: nightly for 14 days, then twice weekly for tablets, or ring replacement every 90 days. Reassess at 8 to 12 weeks.

What to Monitor

Routine endometrial surveillance by transvaginal ultrasound is not indicated for women using standard low-dose formulations. Any new or unexplained vaginal bleeding should trigger immediate investigation regardless of estradiol use. Annual pelvic examination is appropriate. No specific serum estradiol monitoring is required unless clinical concern about systemic absorption arises (for example, in a woman who reports breast tenderness or fluid retention on vaginal cream).

How Long to Continue

GSM is a chronic condition. Unlike hot flashes, which often diminish with time, vaginal and urethral atrophy tends to worsen without ongoing estrogen support. Symptoms typically return within weeks to months of stopping treatment. The Menopause Society states that "duration of use should be based on the woman's treatment goals and periodic reassessment." There is no mandated maximum duration at low vaginal doses.

Original Clinical Decision Framework for Vaginal Estradiol in Women Over 65

The following stepwise approach was developed by the HealthRX medical team to guide clinicians in selecting and monitoring vaginal estradiol therapy in patients aged 65 and older. It synthesizes current guideline recommendations, pharmacokinetic data, and geriatric-specific risk factors into a single workflow.

Step 1. Confirm GSM diagnosis. Obtain vaginal pH (expected >5.0 in GSM), inspect vulvovaginal tissue, exclude infection and malignancy.

Step 2. Review contraindications. Active VTE, unexplained vaginal bleeding, concurrent aromatase inhibitor use without oncology clearance, and estrogen-dependent cancers are stop points.

Step 3. Select formulation by functional status.

• Adequate manual dexterity and no severe atrophy: 10-mcg estradiol tablet twice weekly after loading dose.
• Dexterity limitation or preference for infrequent dosing: estradiol vaginal ring (Estring), replaced every 90 days.
• Severe atrophy requiring faster tissue reconstitution: low-dose vaginal cream (0.5 g, 50 mcg), with plan to reassess absorption at 6 to 8 weeks and transition to tablet or ring if serum estradiol rises above 20 pg/mL.

Step 4. Document rationale distinguishing local from systemic estrogen. This protects against downstream prescriber confusion about WHIMS-era dementia data.

Step 5. Reassess at 12 weeks. Evaluate symptom response, any new vaginal bleeding, and tolerability. If symptoms are controlled, continue indefinitely with annual review.

Step 6. Annual review checklist. Pelvic examination, review of concomitant medications (new aromatase inhibitor? New anticoagulant?), patient satisfaction, and documentation of ongoing indication.

Patient Communication: Addressing the Fears That Prevent Treatment

Older women often refuse vaginal estradiol because they remember the Women's Health Initiative (WHI) oral hormone therapy trial, which showed increased risks of breast cancer, stroke, and cardiovascular events with combined oral estrogen plus progestin. Conflating oral systemic hormone therapy with low-dose vaginal estradiol is the single most common barrier to treatment in women over 65.

The serum estradiol produced by the WHI oral conjugated estrogen dose (0.625 mg daily) is approximately 40 to 60 pg/mL. The serum estradiol produced by the 10-mcg vaginal tablet is approximately 5 pg/mL. These are not the same drug in any physiologically meaningful sense of the word. A clear, direct explanation of this difference, supported by written educational material, converts most hesitant patients. The WHI estrogen-plus-progestin findings are published in JAMA.